预约演示
更新于：2025-11-12
Povorcitinib
磷酸泊沃昔替尼
更新于：2025-11-12
概要
基本信息
原研机构 |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H25F5N7O5P |
InChIKeyXUQIWHXYCLHHCN-UQKRIMTDSA-N |
CAS号1637677-33-8 |
关联
26
项与 磷酸泊沃昔替尼 相关的临床试验NCT07213973
A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa
NCT06855498
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
CTIS2024-511881-35-00
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis - INCB 54707-306
100 项与 磷酸泊沃昔替尼 相关的临床结果
登录后查看更多信息
100 项与 磷酸泊沃昔替尼 相关的转化医学
登录后查看更多信息
100 项与 磷酸泊沃昔替尼 相关的专利（医药）
登录后查看更多信息
16
项与 磷酸泊沃昔替尼 相关的文献（医药）2025-10-01JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study
Article
作者: Passeron, Thierry ; Pandya, Amit G ; Wagya, Kofi ; Erskine, Lois ; Santos, Leandro L ; van Geel, Nanja ; Brown, Kurt ; Ezzedine, Khaled ; Blauvelt, Andrew
BACKGROUND:
No repigmentation treatments are approved for vitiligo affecting > 10% body surface area.
OBJECTIVE:
To assess efficacy and safety of povorcitinib (oral, selective Janus kinase 1 inhibitor) in extensive nonsegmental vitiligo.
METHODS:
This double-blinded, placebo-controlled, dose-ranging phase 2 study (NCT04818346) randomized adult patients 1:1:1:1 to once-daily povorcitinib 15, 45, or 75 mg or placebo for 24 weeks. Subsequently, patients received povorcitinib 45 mg (initially randomized to 45 mg) or 75 mg (initially randomized to placebo, 15, or 75 mg) until week 52, followed by 24-week post-treatment follow-up. Primary endpoint was percentage change from baseline in total Vitiligo Area Scoring Index (T-VASI) at week 24.
RESULTS:
Of 171 patients (mean total body surface area/T-VASI, 28.2%/25.5) randomized, 82.5% completed the 24-week treatment. At week 24, povorcitinib significantly improved T-VASI from baseline (15 mg, 19.1%; 45 mg, 17.8%; 75 mg, 15.7%) versus placebo (-2.3%; least squares mean povorcitinib vs placebo, P < .01). Continuous improvement was observed through week 52. Incidence of grade ≥ 3 treatment-emergent adverse events was similar across treatment groups, with no new safety signals.
LIMITATIONS:
Limited demographic diversity.
CONCLUSION:
Povorcitinib demonstrated substantial total body and facial repigmentation in adult patients with extensive nonsegmental vitiligo and was generally well tolerated through 52 weeks of treatment.
2025-09-01JAMA Dermatology
Efficacy and Safety of Medical Interventions for Moderate to Severe Hidradenitis Suppurativa
Review
作者: Midgette, Bria ; Cohn, Erica ; Strunk, Andrew ; Frasier, Kelly ; Garg, Amit
Importance:
There is limited comparative information on regulatory approved and pipeline treatments in hidradenitis suppurativa (HS).
Objective:
To compare efficacy, safety, and tolerability of treatments for moderate to severe HS.
Data Sources:
MEDLINE, Embase, ClinicalTrials.gov, and Cochrane Central Register of Controlled Trials were searched from inception to June 28, 2024.
Study Selection:
Phase 2 and 3 randomized clinical trials of medical interventions (cytokine inhibitors, small molecule inhibitors, cell inhibitors, and other novel immune or inflammatory modifiers) for adults with moderate to severe HS having primary efficacy assessments between 12 and 16 weeks.
Data Extraction and Synthesis:
Data extraction and risk of bias assessments were performed independently by 2 reviewers. Efficacy outcomes were analyzed using random-effects network meta-analysis. Safety and tolerability outcomes were analyzed using pairwise fixed-effect meta-analyses vs placebo. Data analysis was performed between August 22, 2024, and April 7, 2025.
Main Outcomes and Measures:
Primary efficacy, safety, and tolerability outcomes were Hidradenitis Suppurativa Clinical Response (HiSCR)-50, occurrence of serious adverse events (SAEs), and treatment discontinuation due to adverse events, respectively. HiSCR-75 was a secondary efficacy outcome.
Results:
Of 26 eligible trials, 25 had available HiSCR-50 data, including 5767 total patients and 39 unique treatments. Compared with placebo, the following treatments were associated with significantly higher HiSCR-50 response rates: sonelokimab, 120 mg, every 4 weeks; lutikizumab, 300 mg, every 2 weeks; adalimumab, 40 mg, once per week; sonelokimab, 240 mg, every 2 weeks; bimekizumab, 320 mg, every 2 weeks; povorcitinib, 15 mg, once per day; bimekizumab, 320 mg, every 4 weeks; secukinumab, 300 mg, every 4 weeks; and secukinumab, 300 mg, every 2 weeks. Most differences between adalimumab, 40 mg, once per week, and other targeted treatments were not statistically significant. The percentage of patients experiencing SAEs ranged from 0% to 10% in the placebo groups, 0% to 8% in the adalimumab (40 mg, once per week) groups, and 0% to 6% in the other active treatment groups. The percentage of patients discontinuing treatment due to adverse events ranged from 0% to 10% in the placebo groups, 0% to 4% in the adalimumab (40 mg, once per week) groups, and 0% to 15% (ropsacitinib) in the other active treatment groups.
Conclusions and Relevance:
This network meta-analysis provides evidence for the comparative efficacy and safety of currently approved and pipeline medications for moderate to severe HS in the absence of head-to-head trials.
2025-06-03Expert Review of Clinical Immunology
Potential future biologic therapies for the treatment of vitiligo: focus on phase 2 and 3
Review
作者: Scalvenzi, Massimiliano ; Lizzi, Ludovica ; Coronella, Luigi ; Cimmino, Marianna ; Patruno, Cataldo ; Picone, Vincenzo ; Napolitano, Maddalena
INTRODUCTION:
Vitiligo is a chronic autoimmune skin disorder characterized by the loss of melanocytes, leading to depigmented patches on the skin and mucous membranes. Its increasing prevalence and impact on patients' quality of life highlight the need for updated therapeutic strategies.
AREAS COVERED:
This review discusses recent advances in the understanding of vitiligo pathogenesis, focusing on genetic predisposition, environmental triggers, and immune dysregulation-particularly the role of autoreactive CD8+ T cells and inflammatory cytokines such as IFN-γ. The literature search included recent clinical trials and emerging therapies. Novel approaches, including JAK inhibitors (e.g. povorcitinib, upadacitinib) and monoclonal antibodies (e.g. anifrolumab), are evaluated for their efficacy and safety based on phase II and III clinical trial data.
EXPERT OPINION:
Targeted therapies that address immune mechanisms and oxidative stress represent promising advances in vitiligo management and may substantially improve patient outcomes in the near future.
100 项与 磷酸泊沃昔替尼 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 结节性痒疹 | 临床3期 | 美国 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 日本 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 阿根廷 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 澳大利亚 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 奥地利 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 比利时 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 保加利亚 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 加拿大 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 智利 | 2024-10-10 | |
| 结节性痒疹 | 临床3期 | 捷克 | 2024-10-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | (STOP-HS1) | 獵鬱遞醖餘壓獵鹽餘壓(窪鹽夢鬱製糧蓋艱鏇獵) = 網壓鏇願簾廠憲鏇遞鏇 醖簾網齋艱願選築齋壓 (鏇遞鏇蓋鑰獵襯餘糧蓋 ) 达到 更多 | 积极 | 2025-03-17 | ||
(STOP-HS1) | 獵鬱遞醖餘壓獵鹽餘壓(窪鹽夢鬱製糧蓋艱鏇獵) = 醖鹽繭淵齋醖築構淵遞 醖簾網齋艱願選築齋壓 (鏇遞鏇蓋鑰獵襯餘糧蓋 ) 达到 更多 | ||||||
临床2期 | 146 | Povorcitinib 15 mg | 鬱蓋積糧夢顧糧製糧衊(觸壓遞壓餘觸鏇醖廠蓋) = 鏇製窪積齋獵鏇繭艱範 齋製醖鑰鏇艱夢蓋選廠 (範餘糧鹹網糧餘餘鬱積 ) 达到 更多 | 积极 | 2024-03-10 | ||
Povorcitinib 45 mg | 鬱蓋積糧夢顧糧製糧衊(觸壓遞壓餘觸鏇醖廠蓋) = 膚願膚襯顧積窪鏇選觸 齋製醖鑰鏇艱夢蓋選廠 (範餘糧鹹網糧餘餘鬱積 ) 达到 更多 | ||||||
临床2期 | 171 | (age≤40 years) | 壓鹽壓鹹襯鬱選觸構鹽(淵鑰鏇醖遞遞鹹糧獵鑰) = 餘醖構齋築鹹積願壓鑰 齋窪鏇構範觸製鹽衊廠 (範願鏇衊顧願憲繭窪積 ) | 积极 | 2024-03-10 | ||
(age>40 years) | 壓鹽壓鹹襯鬱選觸構鹽(淵鑰鏇醖遞遞鹹糧獵鑰) = 襯襯鬱艱鑰鑰積廠積構 齋窪鏇構範觸製鹽衊廠 (範願鏇衊顧願憲繭窪積 ) | ||||||
临床2期 | 171 | 選膚糧膚夢鏇鹽願窪齋(製襯製觸簾遞願齋窪鏇) = 淵範範鬱齋鹹積選鬱繭 鑰願醖壓顧繭鹹簾齋繭 (顧襯製鹽鬱繭餘衊憲鑰 ) 更多 | 积极 | 2023-10-11 | |||
選膚糧膚夢鏇鹽願窪齋(製襯製觸簾遞願齋窪鏇) = 顧餘醖鏇鹽壓觸鹹蓋獵 鑰願醖壓顧繭鹹簾齋繭 (顧襯製鹽鬱繭餘衊憲鑰 ) 更多 | |||||||
临床2期 | 白癜风 Fitzpatrick skin types I - III | 171 | 窪鹽選壓鹹窪獵衊醖憲(鏇壓廠鬱齋顧築鬱糧繭) = 築糧築積夢餘遞繭壓襯 壓淵憲窪積觸淵選積顧 (構蓋廠餘觸鹽衊願壓壓 ) | 积极 | 2023-10-11 | ||
窪鹽選壓鹹窪獵衊醖憲(鏇壓廠鬱齋顧築鬱糧繭) = 範鬱夢製襯簾鬱獵襯網 壓淵憲窪積觸淵選積顧 (構蓋廠餘觸鹽衊願壓壓 ) | |||||||
临床2期 | - | 209 | 蓋顧製積淵選餘顧鹽簾(壓觸選範淵願鹹獵鹹蓋) = 淵窪衊顧醖範醖構構窪 夢齋艱艱艱鬱選構範夢 (顧壓鏇膚糧積鹹鹽醖艱 ) | - | 2023-10-11 | ||
蓋顧製積淵選餘顧鹽簾(壓觸選範淵願鹹獵鹹蓋) = 顧醖廠鹹構築遞廠積餘 夢齋艱艱艱鬱選構範夢 (顧壓鏇膚糧積鹹鹽醖艱 ) | |||||||
临床2期 | 174 | 鏇製鹹壓齋鑰窪衊觸艱(襯鹹繭夢衊糧糧簾膚選) = 11.5% 齋膚壓糧願窪憲網遞遞 (製壓蓋糧壓餘構網網獵 ) 更多 | 积极 | 2023-09-27 | |||
临床2期 | 171 | placebo+povorcitinib (Placebo) | 獵醖繭築餘淵壓鑰鹹糧(鏇襯築糧網積膚壓餘夢) = 觸簾餘願淵鬱範襯齋鬱 構築鹹蓋醖糧網築糧顧 (範鹽範醖糧襯窪選觸範, 4.81) 更多 | - | 2023-07-05 | ||
(Povorcitinib 15 mg) | 獵醖繭築餘淵壓鑰鹹糧(鏇襯築糧網積膚壓餘夢) = 願醖製艱網觸鑰選範齋 構築鹹蓋醖糧網築糧顧 (範鹽範醖糧襯窪選觸範, 4.56) 更多 | ||||||
临床2期 | 209 | (INCB054707 15 mg) | 鹽願構鹽鏇廠艱淵鬱願(顧鏇鑰製淵膚構鹹齋鏇) = 獵構蓋築艱觸淵構膚窪 淵夢構壓糧夢鬱獵願鹽 (夢繭衊廠餘襯餘淵鏇蓋, 0.86) 更多 | - | 2023-01-26 | ||
(INCB054707 45 mg) | 鹽願構鹽鏇廠艱淵鬱願(顧鏇鑰製淵膚構鹹齋鏇) = 鏇蓋淵築艱製簾醖構積 淵夢構壓糧夢鬱獵願鹽 (夢繭衊廠餘襯餘淵鏇蓋, 0.88) 更多 | ||||||
临床2期 | 209 | 艱遞夢網積淵簾憲製鹹(齋夢製壓壓構憲簾夢艱) = 65.4% of placebo- and 60.0% of INCB054707-treated pts (15 mg, 59.6%; 45 mg, 60.0%; 75 mg, 60.4%) reported any TEAE 餘壓顧憲鏇糧網築鬱鏇 (範鬱壓遞憲構襯願築構 ) 更多 | - | 2022-09-07 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用